LIVN6033156 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the LivaNova PLC 2.5% 15-MAR-2029 bond (LIVN6033156), covering its key facts, issuer information, and financial specifics. It outlines the bond's issue and maturity dates, face value, and the company's operational segments. The profile also details the interest payment schedule, including the coupon rate, frequency, and upcoming payouts, as well as redemption information.
LivaNova stock stays at USD 3.50 as 52-week range widens
LivaNova stock (LIVN) was quoted at USD 3.50 on September 22, 2026, remaining close to its 50-day moving average of USD 3.52. The 52-week range for the stock is USD 3.10 to USD 4.29, indicating a spread of USD 1.19 or 38.39% of its yearly low. Technical data for the stock on this date showed six sell signals, one neutral signal, and no buy signals.
LivaNova PLC (LIVN) Stock Analysis: A Healthcare Innovator with a 13.98% Upside Potential
LivaNova PLC (LIVN) is a healthcare innovator in medical devices, focusing on Cardiopulmonary and Neuromodulation, with a market cap of $4.31 billion and 10.80% revenue growth. Analysts rate LIVN favorably, with an average target price of $89.10, indicating a 13.98% upside potential. The company shows strong operational efficiency with a 15.40% ROE and $59.87 million in free cash flow, reinvesting for long-term growth rather than paying dividends.
(LIVN) Volatility Zones as Tactical Triggers
This article analyzes Livanova Plc (NASDAQ: LIVN), highlighting a mid-channel oscillation pattern and divergent sentiment across various time horizons. It provides AI-generated trading strategies including a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis indicating weak near-term sentiment but strong long-term prospects. The report also details support and resistance levels for different time horizons.
Director at LivaNova (LIVN) sells 3,500 shares in open-market trade
LivaNova PLC director Francesco Bianchi sold 3,500 Ordinary Shares in an open-market transaction on September 10, 2026, at a weighted-average price of $78.0092 per share, ranging from $77.97 to $78.04. Following this sale, Bianchi directly holds 4,434 shares, and the transaction was not executed under a Rule 10b5-1 trading plan. This insider activity is classified as having a moderate impact and negative sentiment.
LivaNova (NASDAQ: LIVN) Grants 6,291 Derivative Securities to Chief Legal Officer Liddy Anne M.
LivaNova (NASDAQ: LIVN) awarded its Chief Legal Officer, Liddy Anne M., 6,291 derivative securities on September 15, 2026. This transaction represents 100.0% of her total derivative securities holdings post-award. The SEC transaction code for this award is 'A', signifying an acquisition from the company.
Chief legal officer at LivaNova (LIVN) awarded 6,291 stock units vesting through 2029
LivaNova PLC's Chief Legal Officer, Anne M. Liddy, was granted 6,291 Restricted Stock Units (RSUs) on September 15, 2026, under the company's 2022 Incentive Award Plan. These RSUs will vest in tranches over three years, with 20% vesting on March 30, 2027, 40% on March 30, 2028, and the remaining 40% on March 30, 2029, provided vesting conditions are met. Each RSU represents a contingent right to receive one ordinary share of LivaNova PLC and is subject to forfeiture before vesting.
LivaNova Director Francesco Bianchi Disposes 3,500 Shares at $78.01 Each (NASDAQ: LIVN)
LivaNova PLC director Francesco Bianchi sold 3,500 shares of the company at $78.01 per share on September 10, 2026. This transaction reduced his holdings by approximately 44.1%, leaving him with 4,434 shares. The sale details were recorded under code S.
Director at LivaNova (NASDAQ: LIVN) sells 2,300 shares
A director at LivaNova PLC (NASDAQ: LIVN), Story Brooke, sold 2,300 Ordinary Shares of the company on September 4, 2026, for approximately $187,270 at an average price of $81.42 per share. Following this transaction, Brooke directly holds 7,488 Ordinary Shares, and no Rule 10b5-1 trading plan was reported. The sale is considered to have a moderate impact and negative sentiment, according to Rhea-AI.
LivaNova (NASDAQ: LIVN) officer plans 3,500-share sale from 2026 stock award vesting
LivaNova PLC (LIVN) officer Francesco Bianchi plans to sell up to 3,500 shares of common stock, valued at $273,032.19, under Rule 144. These shares originate from a restricted stock unit award that vested on June 15, 2026, as part of the company's equity compensation plan. The filing also notes Bianchi's previous sales of LivaNova common stock during the past three months.
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova PLC announced it will present at two September healthcare conferences in New York City: the Morgan Stanley 24th Annual Global Healthcare Conference on September 14th and the Baird 2026 Global Healthcare Conference on September 15th. CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy Officer Philip Kowalczyk will participate in a fireside chat at Morgan Stanley, with Chief Innovation Officer Ahmet Tezel joining Makatsaria and Shvartsburg at Baird. Webcasts of the discussions will be available for registered attendees and replays will be posted on LivaNova's website.
Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook
Piper Sandler has increased its price target for Livanova (NASDAQ:LIVN) stock from $87 to $90, maintaining an Overweight rating, based on a positive outlook for the company's cardiopulmonary franchise. This revised target suggests a roughly 9% upside from its current trading price of $82.69. The firm's analysis supports Livanova's long-range plan for mid-to-high single-digit growth in this segment from 2025 to 2030, with InvestingPro Tips indicating expected net income growth and an attractive PEG ratio.
Piper Sandler raises Livanova stock price target on cardiopulmonary growth outlook By Investing.com
Piper Sandler has increased its price target for Livanova stock (NASDAQ:LIVN) to $90 from $87, maintaining an Overweight rating, citing a positive outlook for the company's cardiopulmonary franchise. This adjustment follows a detailed modeling exercise that supports Livanova's long-range plan for mid-to-high single-digit growth in this segment from 2025 to 2030. The firm also noted potential for upside in future years' estimates and highlighted that LivaNova recently surpassed Q2 2026 expectations and raised its full-year guidance.
Is LivaNova (LIVN) Fairly Valued As Growth Hopes Meet Reimbursement Risks?
LivaNova (LIVN) has seen recent investor attention, with its stock closing at $78.74, leading to a market value of approximately $4.34 billion. Despite short-term share price fluctuations, the company shows significant year-to-date and one-year returns, driven by clinical innovations in epilepsy, depression, and obstructive sleep apnea. While analysts view the stock as modestly undervalued with a fair value of $84.80, concerns remain regarding healthcare cost controls, reimbursement scrutiny, and competition.
LIVN Looks 23.4% Overvalued on GF Value™
LivaNova PLC (LIVN) is currently viewed as modestly overvalued by 23.4% according to GuruFocus' GF Value™, despite Mizuho maintaining an Outperform rating due to expected growth in cardiopulmonary and improved epilepsy treatment reimbursements. The company has a strong GF Score™ of 76/100, reflecting solid fundamentals and momentum, but insider activity shows net selling. Investors are advised to consider the valuation alongside growth prospects and insider sentiment.
LivaNova (NASDAQ:LIVN) Downgraded by Zacks Research to "Hold"
Zacks Research has downgraded LivaNova (NASDAQ:LIVN) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $83.50. This downgrade follows LivaNova reporting stronger-than-expected quarterly results, with EPS of $1.26 against an estimated $1.09 and a 10.8% year-over-year revenue increase to $390.59 million. The company's stock opened at $78.21, near its 52-week high, with institutional investors holding a significant 97.64% of outstanding shares.
LivaNova PLC (LIVN) Stock Down 3.3% but Still Overvalued -- GF S
LivaNova PLC (LIVN) shares dropped 3.3% to $78.21, but GuruFocus's GF Value™ still identifies the stock as modestly overvalued, trading 23.4% above its intrinsic value estimate of $63.39. Despite a current P/E ratio significantly lower than its historical median, the GF Score™ of 76/100 highlights strong momentum but weaker profitability and valuation. Insider selling activity further suggests caution for potential investors.
Anne Liddy Joins LivaNova as Chief Legal Officer
LivaNova PLC has appointed Anne Liddy as its new Chief Legal Officer, effective August 31. Liddy brings over two decades of experience in legal, regulatory, M&A, and compliance matters for healthcare and life sciences companies, having previously served as general counsel at Hologic Inc. In her new role, she will oversee LivaNova's global legal and compliance functions and join the executive leadership team, aiming to support the company's strategic priorities and global compliance framework.
LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup
LivaNova (NASDAQ:LIVN) demonstrates strong growth fundamentals with consistent EPS and revenue expansion, coupled with high profitability metrics. The stock also presents a promising technical setup, scoring 10 out of 10 in ChartMill's technical rating, indicating a potential breakout from a resistance zone. This combination of robust growth and a favorable technical chart pattern suggests a potential investment opportunity, though investors should be mindful of the company's health rating and debt ratios.
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE
Bank of America Corp DE reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 30.6% in the first quarter, selling 235,233 shares but still retaining 533,017 shares valued at $33.9 million. Institutional investors now own 97.64% of the company's stock. LivaNova recently surpassed earnings expectations, reporting $1.26 per share on revenues of $390.6 million, an increase of 10.8% year-over-year.
LivaNova (LIVN) executive exercises 12,692 SARs and disposes shares
LivaNova PLC's Chief Innovation Officer, Ahmet Tezel, exercised 12,692 Stock Appreciation Rights (SARs) at a base price of $52.68 per share. Concurrently, 8,589 shares were withheld to cover the SARs base price, 1,428 shares for tax liability, and 2,675 shares were sold on the open market at a weighted-average price of $77.7355. After these transactions, Tezel holds 12,691 SARs and 6,090 ordinary shares.
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to $4.30-$4.40, citing improved market share, Essenz upgrade cycles, and favorable Medicare reimbursement. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and provided updates on its innovation pipeline, including next-generation oxygenators and advancements in its Obstructive Sleep Apnea program.
LivaNova PLC (LIVN) employee stock rights lead to 2,675-share sale
LivaNova PLC has reported a planned sale of 2,675 shares of common stock, stemming from the exercise of employee stock appreciation rights. The transaction, valued at $209,942.40, is scheduled for August 11, 2026, and will be executed through Merrill Lynch as a broker-assisted cashless exercise on NASDAQ. This Form 144 filing provides transparency regarding the upcoming sale of employee-held shares.
Price-Driven Insight from (LIVN) for Rule-Based Strategy
This article provides a price-driven insight into Livanova Plc (NASDAQ: LIVN) for rule-based trading strategies. It highlights weak near-term sentiment challenging long-term strength, with support being tested. The analysis identifies an exceptional 28.8:1 risk-reward setup targeting an 8.4% gain against 0.3% risk, and outlines institutional trading strategies (Position, Momentum Breakout, Risk Hedging) based on AI models across different time horizons.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant swing back to profitability in Q2 2026, with sales of US$390.59 million and net income of US$108.57 million. This turnaround, bolstered by the PMA approval of its aura6000 system, suggests a stronger earnings profile and potential for future growth in neuromodulation and cardiopulmonary demand. However, the company still faces risks from pricing pressure, reimbursement limits, and high R&D spending.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This performance, along with the recent PMA approval of its aura6000 system for obstructive sleep apnea, strengthens its investment narrative, though risks like pricing pressure and R&D spending persist. Despite the positive earnings, the stock was down 7.6%, prompting an exploration of how these results reshape its financial outlook.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This improvement was driven by strong first-half sales of US$752.85 million and a shift from a prior-year loss, strengthening the company's investment narrative. The company's recent PMA approval for the aura6000 system for obstructive sleep apnea is expected to diversify its revenue streams, though potential challenges like pricing pressure and R&D costs remain.
Price to earnings forward of LivaNova Plc – FWB:LIA
This article provides a brief overview of LivaNova Plc's forward price-to-earnings ratio on the Frankfurt Stock Exchange (FWB:LIA). It highlights that the market is currently closed with no trades, and the content is primarily focused on the financial data of the company. The page also offers various tools and resources available on the TradingView platform.
LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...
LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, reflecting robust operational performance. Despite these positive results, the company lowered its free cash flow guidance due to increased capital spending and an OSA program timeline delay.
FMR LLC (LIVN) discloses 5.8% LivaNova stake in Schedule 13G filing
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting power over most shares and both entities having sole dispositive power. This filing indicates a passive investment, not intended to influence company control.
LivaNova PLC Stock 12‑Month Price Target Raised to $88.78, Implies 4% Upside
LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The consensus rating from 11 analysts remains a "Buy," with 8 Buy recommendations, 2 Holds, and 1 Sell.
LivaNova Plans for Early 2027 Launch of Aura6000 for Obstructive Sleep Apnea
LivaNova, a medical-device firm, plans an early 2027 launch for its Aura6000 device designed to treat obstructive sleep apnea. The company employs an innovation strategy focused on differentiated products and strong commercialization through salesforce relationships, similar to larger competitors. This strategy aims to create pricing premiums through meaningful innovation, either internal or augmented by emerging technology acquisitions.
LivaNova PLC 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LIVN) 2026-08-05
LivaNova PLC (NASDAQ: LIVN) has released its Q2 2026 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.17, and revenue of $390.60 million, a 10.81% year-over-year increase, beating estimates by $10.02 million. This presentation provides details on their financial performance for the quarter.
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LivaNova (LIVN) reported strong Q2 2026 earnings, with revenue of $390.6 million and EPS of $1.26, surpassing Wall Street expectations. The company exceeded consensus estimates for net sales in Neuromodulation, Cardiopulmonary, and Other segments. Despite the positive results, LivaNova's stock performance over the past month lagged the S&P 500, though it currently holds a Zacks Rank #2 (Buy).
LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance
LivaNova plc (LIVN) exceeded analyst expectations for its Q2 earnings, reporting an EPS of $1.26 against an estimated $1.09, and revenue of $390.6 million compared to the $380.57 million consensus. The company also provided optimistic guidance for FY2026 EPS, projecting $4.30-$4.40, which is above the analyst consensus of $4.25. The stock price showed a significant decrease of 10.82% on the day.
Earnings Flash (LIVN) LivaNova PLC Reports Q2 Revenue $390.6M, vs. FactSet Est of $380.5M
LivaNova PLC (LIVN) announced Q2 revenue of $390.6 million, surpassing the FactSet estimate of $380.5 million. The company also reported Q2 adjusted EPS of $1.26 per share, exceeding the FactSet estimate of $1.09, and raised its fiscal 2026 adjusted EPS outlook to a range of $4.30 to $4.40, against an earlier FactSet estimate of $4.25.
LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC reported strong second-quarter 2026 results, with reported revenue growth of 10.8% and constant-currency growth of 9.8%. The company raised its full-year 2026 revenue and adjusted diluted earnings per share guidance, citing sustained performance in its Cardiopulmonary and Neuromodulation businesses. LivaNova also announced a long-term agreement with Thermo Fisher Scientific to enhance oxygenator component supply, aiming to meet unmet customer demand.
LivaNova PLC stock hits 52-week high at 85.28 USD
LivaNova PLC (LIVN) stock reached a new 52-week high of $85.28, reflecting a 92.84% one-year total return and a market capitalization of $4.68 billion. Despite this surge, InvestingPro analysis suggests the stock is still slightly undervalued. The company also announced strategic leadership changes and promising data for its sleep apnea therapy.
LivaNova PLC stock hits 52-week high at 85.28 USD By Investing.com
LivaNova PLC stock reached a new 52-week high of $85.28, reflecting a significant upward trend with a 92.84% 1-year total return. The company, with a market capitalization of $4.68 billion, is considered slightly undervalued according to InvestingPro, which also highlights its low P/E ratio relative to near-term earnings growth. Recent strategic developments include new analyst coverage, promising clinical data for its sleep apnea therapy, and changes to its board and executive team.
(LIVN) Price Dynamics and Execution-Aware Positioning
This article analyzes Livanova Plc (NASDAQ: LIVN) price dynamics, identifying a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It highlights an exceptional 26.2:1 risk-reward short setup and provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
LivaNova PLC (LIVN) Financial Health: Profitability & Balance Sheet Analysis
LivaNova PLC (LIVN) has a robust financial status with a current financial score of 7.86, ranking 54 out of 199 in its industry. The company reported a significant year-over-year revenue increase of 14.33% and a net profit increase of 106.81%, demonstrating high operating efficiency. Key financial metrics like cash and cash equivalents, total assets, and cash flow from operating activities contribute to its strong performance.
LivaNova PLC (LIVN) Institutional Confidence
This article analyzes the institutional confidence in LivaNova PLC (LIVN), reporting its current institutional shareholding score as 10.00, which ranks 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding has increased by 3.56% quarter-over-quarter, with HOTCHKIS & WILEY identified as the largest institutional shareholder. The report also lists other major institutional shareholders and their recent changes in holdings.
LivaNova PLC (LIVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for LivaNova PLC (LIVN), noting its current valuation score is 6.28, ranking 184 out of 199 in its industry. The company's P/E ratio stands at 41.18, significantly above its recent low. However, key P/B, P/S, and P/CF data are not yet disclosed.
LivaNova PLC (LIVN) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for LivaNova PLC (LIVN), detailing its volatility, financial risk, and investment risk. LIVN has a current risk assessment score of 7.91, ranking 27th in the Healthcare Equipment & Supplies industry, with a beta of 0.87 indicating less volatility than the market. The report includes various metrics such as VaR, maximum drawdown, daily returns, Sharpe Ratio, skewness, and liquidity measures to give a comprehensive overview of the stock's risk profile.
LIVN|LivaNova PLC|Price:80.640|Chg%:+2.450
LivaNova PLC (LIVN) has relatively healthy fundamentals and high growth potential, though its performance has turned to a loss from a profit. The company is considered fairly valued within the Healthcare Equipment & Supplies industry. Institutional ownership is high, and analysts have a "Buy" rating with a target price of 84.93, suggesting an upside.
LivaNova Number of Employees 2026 | Employee Count & Headcount Data
LivaNova Plc (LIVN) had approximately 3,366 employees worldwide as of March 2026, representing a 9.6% growth from 2023. The company, headquartered in London, United Kingdom, is actively hiring with 294 active job postings in 2026, despite a slight decline in new postings per month. Its workforce is primarily concentrated in North America, and the average salary is $94,626 globally.
LivaNova PLC (LIVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of LivaNova PLC (LIVN), detailing its price momentum score, current trading range, and indicators. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy or sell signals. The analysis also features an FAQ section clarifying technical ratings and moving averages.
LivaNova PLC (LIVN) Balance Sheet
This article provides a detailed balance sheet for LivaNova PLC (LIVN), offering both quarterly and annual financial data. It allows users to analyze the company's financial health, fundamentals, and key ratios related to liquidity, leverage, and return on equity. The page also includes FAQs defining important balance sheet metrics and providing quick answers about LIVN's cash, liabilities, assets, and shareholders' equity.
LivaNova PLC (LIVN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of LivaNova PLC (LIVN) focusing on its dividend history. It states that the company has not distributed any dividends over the past five years. Key financial figures like market cap and P/E ratio are also presented.
LivaNova PLC (LIVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of LivaNova PLC's (LIVN) revenue breakdown, focusing on regional contributions. As of the stated update, the company has not disclosed detailed business segment data. The revenue figures show that the United States is the largest contributor, followed by the Rest of World and Europe.
